Galapagos Exits Cell Therapy Programs Amid Industry Realignment
Galapagos NV (NASDAQ: GLPG) has announced a decisive exit from cell therapy, closing its dedicated division and eliminating approximately 365 roles worldwide. This move positions Galapagos among a growing roster of top-tier pharma companies, such as Novo Nordisk and Takeda, who have recently scaled back or fully withdrawn from cell therapy investments and programs, reflecting key macroeconomic and industry pressures.
Macro Trends Reshaping Cell Therapy Investments
While the global cell and gene therapy market is expected to grow from $25 billion in 2025 to more than $117 billion by 2034, the space faces mounting challenges, including operational complexity, capital intensity, regulatory uncertainty, and the evolving reimbursement environment. High-profile exits by companies like Takeda, which recently ended all cell therapy R&D as part of its strategic portfolio reprioritization, and Novo Nordisk, which terminated large-scale cell therapy programs, indicate an industry-wide reassessment of where value and scalability can be achieved in advanced therapies.
The market’s expansion—driven by innovation in cancer immunotherapy and personalized medicine—has not shielded it from volatility. Financial discipline, demands for operating leverage, and shifting investor sentiment are prompting companies to concentrate on scalable, differentiated assets over complex cell-based modalities. The closure of Galapagos’ sites in Leiden, Basel, Princeton, Pittsburgh, and Shanghai underscores these pressures.
Strategic Refocus and Pipeline Optimization
Galapagos reports that capital will now be redeployed into high-impact licensing, acquisition, and R&D initiatives in inflammation, immunology, and autoimmune disease. This exit is projected to cost €150–€200 million ($175–$233 million) in restructuring charges and €100–€125 million ($117–$146 million) in wind-down costs. The company will provide updated financial guidance with its Q3 earnings.
Post-restructuring, Galapagos’ clinical attention will center on GLPG3667, a TYK2 inhibitor in Phase 2 trials for systemic lupus erythematosus and dermatomyositis, as well as two earlier-stage small-molecule programs for inflammatory diseases. This evolution mirrors sector-wide movement away from capital-heavy cell therapy platforms toward more agile, partnership-driven R&D and therapeutics.
Competitive Context: A Shift in Cell Therapy Programs
Multiple leading biopharma organizations, including Novo Nordisk, Takeda, and others like Gilead’s Kite and Roche/Genentech, have announced their own exits or strategic pullbacks from cell therapy investments in 2025. The rationale frequently includes capital reallocation, pipeline optimization, and adapting to the commercial realities of advanced therapy manufacturing and market adoption.
As pharma leaders consolidate resources around scalable, next-generation modalities, cell therapy’s boom-and-bust cycle offers cautionary lessons for investors and operators pursuing innovation in high-cost, high-reward domains.
